Next Article in Journal
Plant-Derived Mucilage: A Natural Antioxidant with Multi-Functional Applications in Food, Cosmetics, and Health
Previous Article in Journal
Development of the Rheumatic Fever Care Coordination System (RFCCS) for Aotearoa New Zealand
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Co-Crystallization Adducts of Carvedilol with Carboxylic Acids: Design and Characterization †

1
Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
2
Doctoral School, “Victor Babeş” University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania
3
Advanced Instrumental Screening Center, Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
4
Faculty of Industrial Chemistry and Environmental Engineering, University Politehnica Timisoara, 2 Victoriei Square, 300006 Timisoara, Romania
*
Author to whom correspondence should be addressed.
Presented at the International Conference on Interdisciplinary Approaches and Emerging Trends in Pharmaceutical Doctoral Research: Innovation and Integration, Timisoara, Romania, 7–9 July 2025.
Proceedings 2025, 127(1), 10; https://doi.org/10.3390/proceedings2025127010
Published: 22 September 2025
Carvedilol (CARV) belongs to the group of non-selective beta and alpha-1 adrenergic receptor antagonists and is indicated for hypertension and chronic heart failure. The disadvantages related to its poor bioavailability, as a consequence of its low water solubility, are one of the reasons that led researchers to resort to methods to improve its physicochemical properties [1]. Pharmaceutical co-crystals have been shown to positively influence the bioavailability, thermal stability, photostability, and intrinsic dissolution rate of drugs [2,3,4].
The current study aims to address a strategy for modifying the physicochemical properties of a candidate drug with limitations, resulting in binary adducts with an improved biopharmaceutical profile.
This study integrates thermal methods of analysis, such as thermogravimetry (TG) and derivative thermogravimetry (DTG) as well as spectroscopic techniques, including universal-attenuated total reflectance Fourier-transform infrared (UATR-FTIR) spectroscopy and powder X-ray diffractometry (PXRD) applied to investigate the formation of CARV adducts with two carboxylic acids, namely, malonic and succinic acid, in a 1:1 molar ratio (CARV: CARBOXYLIC ACIDS).
The IR spectra of the adducts showed shifts in the CARV characteristic bands toward different wavenumbers compared to the parent substances’ spectra, confirming the formation of co-crystals with the two carboxylic acids. Thermal analysis data reveal a great stability of CARV, characterized by a single decomposition step, starting at 220 °C, with a continuous mass loss in the temperature range of 220–450 °C (DTGpeak at 331 °C), resulting in a residual mass of 29.88%. The co-crystallization products of CARV with carboxylic acids exhibit a different thermoanalytical profile than those of the parent compounds, demonstrating the interaction of the components with the formation of a new chemical entity. The results of the PXRD analysis highlight the following phenomena in the diffraction patterns of the binary adducts: 1. the disappearance of the intense crystalline reflections of the parent substances; 2. the shift in the diffraction peaks of CARV towards other 2θ values and drastic decrease in their intensity; 3. the appearance of new crystalline reflections, all of which suggest the formation of new chemical entities different from the parent compounds, which have the specific crystalline structure identified with the adducts.
The collected data proved to be a valuable source of structural knowledge on co-crystals, promoting strategic design and optimization of the physicochemical properties and pharmacological profiles of drugs at the molecular level, providing significant contributions to scientific research and practical applications.

Author Contributions

Conceptualization, E.-T.N., I.L. and L.S.; methodology, E.-T.N., A.R., I.L., A.L. and L.S.; validation, A.R., A.L. and L.B.; formal analysis, E.-T.N. C.M., I.M. and L.B.; investigation, E.-T.N., I.M., A.R. and C.M.; resources, E.-T.N., C.M., I.L. and A.L.; data curation, I.M., L.B., I.L. and A.L.; writing—original draft preparation, E.-T.N.; writing—review and editing, L.S.; supervision, L.S.; project administration, E.-T.N. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions are included in the abstract, further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Niţu, E.T.; Ridichie, A.; Temereancă, C.; Mitrofan, I.; Buliga, L.; Simu, S.; Muntean, C.; Rusu, G.; Ledeţi, I.; Ledeţi, A.; et al. Study of Carvedilol–β-Cyclodextrin Derivatives Interactions. Processes 2025, 13, 1141. [Google Scholar] [CrossRef]
  2. Sun, Z.H.; Yang, Z.; Zhang, Y.; Xu, H.; Liu, R.M.; Ding, D.Z.; Li, Y.; Zhu, Y.J.; Li, M.; Leng, P. Synthesis, Characterization, Solubility and Photostability Enhancement of Felodipine Co-Crystals Featuring a Novel Single-Crystal Structure. J. Mol. Struct. 2025, 1332, 141678. [Google Scholar] [CrossRef]
  3. Sopyan, I.; Layyareza, R.T.; Megantara, S.; Marvita, S.S. Carvedilol Solubility Enhancement by Multicomponent Crystallization with Coformers of Benzoic Acid, Isonicotinamide, and Saccharin. Pharmacia 2023, 70, 283–290. [Google Scholar] [CrossRef]
  4. Eesam, S.; Bhandaru, J.S.; Naliganti, C.; Bobbala, R.K.; Akkinepally, R.R. Solubility Enhancement of Carvedilol Using Drug–Drug Cocrystallization with Hydrochlorothiazide. Future J. Pharm. Sci. 2020, 6, 77. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Nițu, E.-T.; Buliga, L.; Mitrofan, I.; Ridichie, A.; Muntean, C.; Ledeţi, I.; Ledeți, A.; Sbârcea, L. Co-Crystallization Adducts of Carvedilol with Carboxylic Acids: Design and Characterization. Proceedings 2025, 127, 10. https://doi.org/10.3390/proceedings2025127010

AMA Style

Nițu E-T, Buliga L, Mitrofan I, Ridichie A, Muntean C, Ledeţi I, Ledeți A, Sbârcea L. Co-Crystallization Adducts of Carvedilol with Carboxylic Acids: Design and Characterization. Proceedings. 2025; 127(1):10. https://doi.org/10.3390/proceedings2025127010

Chicago/Turabian Style

Nițu, Ema-Teodora, Luciana Buliga, Ioana Mitrofan, Amalia Ridichie, Cornelia Muntean, Ionuţ Ledeţi, Adriana Ledeți, and Laura Sbârcea. 2025. "Co-Crystallization Adducts of Carvedilol with Carboxylic Acids: Design and Characterization" Proceedings 127, no. 1: 10. https://doi.org/10.3390/proceedings2025127010

APA Style

Nițu, E.-T., Buliga, L., Mitrofan, I., Ridichie, A., Muntean, C., Ledeţi, I., Ledeți, A., & Sbârcea, L. (2025). Co-Crystallization Adducts of Carvedilol with Carboxylic Acids: Design and Characterization. Proceedings, 127(1), 10. https://doi.org/10.3390/proceedings2025127010

Article Metrics

Back to TopTop